• Revenue up 3% to $1.9 billion
• Gross margin up 6% to $173.9 million
• Underlying EBITDA up 3.1% to $49 million
• $47.3 million provision for Infinity Group debt

Paragon Care Limited, one of Asia Pacific's leading diversified healthcare distributors and manufacturers, has reported its financial results for the half-year ended 31 December 2025 (1H26). The Group delivered on its organic and regional growth strategy, with revenue increasing by 3% to $1,904,873,000 and gross margin up 6% to $173,943,000. Underlying EBITDA, which excludes the impact of non-recurring and certain other items, increased by 3.1% to $49,032,000 with contributions from geographic segments. The highly complementary acquisitions of the Somnotec Group in December 2025 and the expected H2FY26 acquisition of Haju Medical will make positive earnings contributions in the second half of FY26. However, the reported net loss for the Consolidated Group amounted to $(21,274,000), largely attributable to a $47.3 million provision recorded against debt owed by the Infinity Retail Pharmacy Group. Paragon Care continues to engage actively with the receivers and administrators of Infinity Group as a significant creditor, and remains cautiously optimistic that the administration process will be satisfactorily resolved, though the timing and quantum of any trade and non-trade loans/receivables recovery remains uncertain.